1	Title:
2	Molecular epidemiology of invasive Group A Streptococcal infections before and after the
3	COVID-19 pandemic in Switzerland
4	Authors:
5	Angeliki M. Andrianaki ¹ , Jessica Franz ¹ , Federica Andreoni ¹ , Judith Bergada-Pijuan ¹ ,
6	Thomas C. Scheier ¹ , Tanja Duwe ¹ , Marc Pfister ¹ , Helena Seth-Smith ² , Tim Roloff ² , Natalia
7	Kolesnik-Goldmann ² , Sara H. Burkhard ³ , Alexia Cusini ⁴ , Urs Karrer ⁵ , Christian Rüegg ⁶ ,
8	Adrian Schibli ⁷ , Jacques Schrenzel ⁸ , Stefano Musumeci ⁹ , Roger D. Kouyos ¹ , Adrian Egli ² ,
9	Silvio D. Brugger ¹ , Annelies S. Zinkernagel ^{1*}
10	Affiliations:
11	1. Department of Infectious Diseases and Hospital Epidemiology, University Hospital
12	Zurich, University of Zurich, Zurich, Switzerland
13	2. Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
14	3. Division of Infectious Diseases, Department of Medicine, Hospital of Uster, Uster,
15	Switzerland
16	4. Division of Infectious Diseases, Cantonal Hospital of Grisons, Chur, Switzerland
17	5. Division of Infectious Diseases, Department of Medicine, Cantonal Hospital of
18	Winterthur, Winterthur, Switzerland
19	6. Division of Infectious Diseases, Department of Medicine, Hospital of Wetzikon,
20	Wetzikon, Switzerland
21	7. Division of Infectious Diseases and Hospital Epidemiology, Zurich City Hospital,
22	Zurich, Switzerland
23	8. Division of Laboratory Medicine, Geneva University Hospitals, Switzerland; Division
24	of Infectious Diseases, Geneva University Hospitals, Switzerland.

- 9. Department of General Internal Medicine, Department of Medicine, Geneva
 University Hospital, 1205 Geneva, Switzerland.
- 27
- 28 Corresponding author:
- 29 Prof. Dr. Dr. med. Annelies Zinkernagel
- 30 Department of Infectious Diseases and Hospital Epidemiology
- 31 University Hospital of Zurich,
- 32 Raemistrasse 100, 8091 Zurich, Switzerland
- 33 Tel: + 44 255 33 22
- 34 E-Mail: annelies.zinkernagel@usz.ch
- 35
- 36 Keywords: Group A Streptococcus, GAS, COVID-19, emm-type, FT-IR spectroscopy, whole
- 37 genome sequencing, WGS

38 Abstract

39 Group A Streptococcus (GAS, aka Streptococcus pyogenes) poses a significant public health 40 concern, causing a diverse spectrum of infections with high mortality rates. Following the 41 COVID-19 pandemic, a resurgence of invasive GAS (iGAS) infections has been documented, 42 necessitating efficient outbreak detection methods. Whole genome sequencing (WGS) serves 43 as the gold standard for GAS molecular typing, albeit constrained by time and costs. This 44 study aimed to characterize the post-pandemic increased prevalence of iGAS on the molecular 45 epidemiological level in order to assess whether new, more virulent variants have emerged, as 46 well as to assess the performance of the rapid and cost-effective Fourier-transform infrared 47 (FT-IR) spectroscopy as an alternative to WGS for detecting and characterizing GAS 48 transmission routes. A total of 66 iGAS strains isolated from nine Swiss hospitals during the 49 COVID-19 post-pandemic increased GAS prevalence were evaluated and compared to 15 50 strains collected before and 12 during the COVID-19 pandemic. FT-IR measurements and 51 WGS were conducted for network analysis. Demographic, clinical, and epidemiological data 52 were collected. Skin and soft tissue infection was the most common diagnosis, followed by primary bacteremia and pneumonia. Viral co-infections were found in 25% of cases and were 53 54 significantly associated with more severe disease requiring intensive care unit admission. 55 WGS analysis did not reveal emerging GAS genetic distinct variants after the COVID-19 56 pandemic, indicating the absence of a pandemic-induced shift. FT-IR spectroscopy exhibited 57 limitations in differentiating genetically distant GAS strains, yielding poor overlap with 58 WGS-derived clusters. The emm1/ST28 gebotype was predominant in our cohort and was 59 associated with five of the seven deaths recorded, in accordance with the molecular epidemiological data before the pandemic. Additionally, no notable shift in antibiotic 60 61 susceptibility patterns was observed. Our data suggest that mainly non-pathogen related factors contributed to the recent increased prevalence of iGAS. 62

63 **Introduction**

64 Group A Streptococcus (GAS, aka Streptococcus pyogenes) is a pathobiont that causes a wide 65 spectrum of infections, ranging from pharyngitis and superficial skin infections to severe 66 invasive infections, such as necrotizing fasciitis, pneumonia or meningitis associated with 67 high mortality and morbidity rates, with 500,000 estimated deaths annually worldwide [1-3]. After a historically low incidence of GAS infections during the COVID-19 pandemic, an 68 69 alarmingly increasing incidence of invasive GAS (iGAS) infections has been reported, since 70 October 2022, in many European countries and in the USA, mostly among children under 10 71 years of age, including many fatalities [4-7]. Also in Switzerland, since November 2022, a 72 fourfold increase of the registered iGAS infections in children, including four deaths, has been 73 reported compared to the pre- COVID-19 pandemic era [8]. So far, there is no evidence for 74 the emergence of a more virulent clone [9, 10]. In the United Kingdom the pre-pandemic 75 predominant M1uk clone was detected in the majority of the GAS strains isolated during the 76 December 2022 outbreak [9]. The causes of the resurgence of iGAS remain somewhat 77 elusive.

The detection and management of outbreaks, particularly in the case of GAS, rely on 78 79 understanding transmission routes and genetic diversity. Molecular typing by whole genome 80 sequencing (WGS) or conventional (Sanger) sequencing of the hypervariable N-terminal 81 region of the *emm* gene, encoding the surface M protein [11], is crucial for epidemiological 82 studies and outbreak investigations, although it is time-consuming, expensive and requires 83 expertise [12, 13]. Alternatively, Fourier-transform infrared (FT-IR) spectroscopy may 84 provide a cost-effective approach for outbreak analysis by generating a biochemical fingerprint of the bacterial composition using the full infrared spectrum (4000-400 cm^{-1}), 85 86 albeit with variable cluster defining cut-offs among different bacterial species and dependencies on growth conditions [13-19]. 87

The aim of this study was to evaluate whether any GAS genomic variations had emerged. To this end, we compared iGAS strains isolated before, during, and after the COVID-19 pandemic (from January 2013 until May 2023) from patients hospitalized in nine hospitals in the Regions of Zurich, Graubünden and Geneva using the current gold standard WGS. Furthermore, we aimed to assess whether FT-IR spectroscopy is a reliable alternative for a time-efficient detection of GAS outbreaks compared to WGS.

94 Materials and Methods

95 *Study period, population, clinical and epidemiological information*

96 The study encompassed 93 strains sourced from the same number of patients with GAS 97 infection. Among these, 15 strains were retrospectively identified between January 2013 and 98 December 2019, 18 strains were retrieved from the COVID-19 pandemic period between 99 February 2020 and September 2022. The remaining 60 strains were prospectively identified 100 during the latest iGAS resurgence (October 2022 to May 2023) from patients hospitalized in 101 nine Swiss hospitals: University Hospital Zurich, University Hospital of Geneva, City 102 Hospital of Zurich, Cantonal Hospital of Graubünden, Cantonal Hospital of Winterthur, 103 Regional Hospitals of Wetzikon, Uster, Limmatal, and Männedorf. These hospitals 104 collectively serve an area inhabited by approximately 2 million individuals. Only three of the 105 participating hospitals admitted pediatric patients. Two patients did not have an invasive 106 infection (GAS_036 and GAS_037), but were included in the study because they were related 107 to a patient who died from iGAS infection (GAS_035). Basic demographical, clinical, and 108 epidemiological data were collected for 74 patients from electronic health records, including 109 sex, age, diagnosis, co-infections, sampling date and site, as well as the geographical location 110 of the sampling. Outcomes included admission to the intensive care unit (ICU), intubation and 111 death related to iGAS. No clinical data were available from the Regional Hospitals of 112 Limmatal and Männedorf.

In order to determine the prevalence of GAS over the years, the number of all GAS strains detected by culture or molecular techniques in patients admitted to the University Hospital of Zurich between January 2012 and December 2023 was collected. The GAS strains originating from blood, joint punctures, cerebrospinal fluid, bronchoalveolar lavage, pleura fluid and soft tissue were defined as invasive. The definition of the Centre for Disease Control regarding invasive infection was adopted [20].

120 *Ethics approval*

121 This study was approved by the Ethic Committee of Nordwest- and Central Switzerland with

the agreement of all Swiss Ethical Committees (BASEC-ID: 2019-01291 as part of the Swiss

123 Pathogen Surveillance Platform, www.spsp.ch). Patients declining to sign a general consent or

124 any other declining statement against using data for research purposes were excluded.

125

126 *Bacterial strains*

93 GAS strains were collected from the same number of patients hospitalized in the nine
hospitals mentioned above and stored at -80°C. Species identification of all samples was
carried out using Matrix Assisted Laser-Desorption Ionization – Time of Flight (MALDITOF) (MBT Compass 4.1, Bruker Daltonics, Bremen, Germany) using the database BDAL
DB.13.

132

133 Sample preparation for FT-IR spectroscopy and WGS

134 Three to five macroscopically identical colonies were subcultured on 5 % sheep blood agar 135 plates (Biomérieux) for 24 ± 2 hours at 37° C in a static incubator in the presence of 5% CO₂. 136 For FT-IR spectroscopy, a 1µl-loop was overloaded with bacteria cells that were then 137 resuspended in 50 μ l ethanol solution (70% v/v) in a 1.5 ml tube containing metal rods. The 138 suspension was then vortexed extensively and 50 μ l of deionized water were added, followed 139 by another round of vortexing. Fifteen microliters of the homogenized bacterial suspension 140 were placed on a 96-spot silicon plate (Bruker Daltonics, Bremen, Germany) in four technical 141 replicates per bacterial isolate. The plates were dried at 37°C for approximately 20 minutes 142 followed by infrared measurements. For WGS, a lawn was streaked from frozen stocks and 143 samples were processed as previously described [21, 22].

144

145 *Infrared measurements*

An IR-Biotyper (Bruker Daltonics) was used for all measurements according to the manufacturer's instructions and as previously described [19]. In brief, 12 μ l of test standard 1 and 2 (ITRS 1/ ITRS 2) were placed on the 96-spot silica plate and used as controls. The samples were measured using the OPUS software v8.2.28 (Bruker Daltonics), detecting carbohydrates spectra within the wavenumber range of 1200 and 900 cm⁻¹. Data analysis was performed using the same software. Isolates with three or more valid replicates in the same run were included in the analysis.

153

154 Whole genome sequencing of isolates and comparative genomics

Whole genome sequencing of the clinical isolates was performed at the Institute for Medical Microbiology, University of Zurich, Switzerland as previously described [21]. *Emm*-typing was extrapolated from the WGS data using the *emm*-typing tool [23] and MLST typing was inferred from the WGS data using MLST v.2.7.6 [24], which makes use of the PubMLST website (<u>https://pubmlst.org/</u>) developed by Keith Jolley [25] and sited at the University of Oxford. The development of that website was funded by the Wellcome Trust.

161 De novo assemblies were built with SPAdes v.3.14.1 using the -careful option [26]. 162 Annotation of the resulting assemblies was performed with Prokka v1.14.6 [27]. The created 163 GFF files were used as input to Roary v3.13.0 to construct the pangenome, for which we used 164 the command -e -mafft that generates a multi-fasta alignment of the core genes [28]. The 165 average nucleotide identity (ANI) was inferred with pyani v0.2.12 choosing the method 166 ANIm, which makes use of MUMmer / NUCmer to align the input sequences [29]. 167 Phylogenetic trees were inferred from the aligned core genome using IQTREE [30] under the 168 GTR+G+I model. Trees and metadata were processed and plotted using the R-packages ape 169 [31] and ggtree [32].

170 The overlap between clusters derived from FT-IR and whole bacterial genome data171 (specifically Average Nucleotide Identity, ANI) was quantified as outlined in Scheier *et al*

172 [19] . In brief FT-IR clusters were inferred by cutting the hierarchical (UPGMA) clustering 173 tree derived from the Euclidean distance of the FT-IR spectra at a given height, which was 174 varied over a broad range. ANI-based clusters were defined as the components of the network 175 obtained by connecting those pairs of nodes whose ANI was above a given threshold. We 176 used the v-measure to quantify the overlap between these two networks.

The genomic data with matched phenotypic information can be downloaded here (<u>National</u>
Center for Biotechnology Information (nih.gov)).

179

180 Antibiotic susceptibility testing

181 Antibiotic susceptibility testing to penicillin, clindamycin and erythromycin was conducted on 182 pandemic and post-pandemic GAS strains as part of the routine microbiological assessment. 183 The Kirby-Bauer method was perfored in line with the recommendations of the European 184 Committee on Antimicrobial Susceptibility Testing (EUCAST) in the ISO accredited Institute 185 of Molecular Microbiology (IMM) in Zurich. Briefly, a 0.5 McFarland standard inoculum 186 preparation was used. Mueller-Hinton agar was supplemented with 5% defibrinated horse 187 blood and 20 mg/L β -NAD (MH-F agar). After evenly inoculating the agar with the bacterial 188 suspension, antimicrobial disks were applied to the agar surface. To detect inducible 189 clindamycin resistance, erythromycin and clindamycin disks were placed 12-16 mm apart 190 (edge to edge). The plates were incubated at $35 \pm 1^{\circ}$ C in with 4-6% CO₂ for 18 ± 2 hours, 191 after which zones of inhibition were measured to determine susceptibility based on EUCAST 192 breakpoint tables (version 14.0).

193

194 Data Analysis

For the patients' clinical characteristics we performed a descriptive statistical analysis. Continuous variables were presented as mean with range, except for age which was presented as median with range. Categorical variables were presented as frequency tables. For the 198 association of the patient-related factors with the severity of the disease we chose as 199 dependent variables the ICU admission and the all-cause in-hospital mortality and performed 200 a univariable analysis. Due to the rare event problem for the case of obesity (4/74 incidences), 201 we collapsed this variable with two other related medical conditions, diabetes mellitus and 202 cardiovascular disease (CVD), based on their clinical relevance and exhibited overlap. 203 Variables that demonstrated significant (or marginally significant) associations (p<0.07) in 204 the univariable analysis were taken to multivariable binary logistic regression analysis. The 205 significance level was set at p < 0.05. The model fit was evaluated using the Hosmer-206 Lemeshow test. All analyses were performed with IBM SPSS Statistics V26 (IBM Corp., 207 Armonk, NY, USA).

208

209 Funding information

This study was supported by the University Of Zurich CRPP Personalized Medicine Of Persisting Bacterial Infections Aiming to Optimize Treatment and Outcome to S.D.B, and A.S.Z.; and by grant (INOV00121) from University Hospital Zurich to T.C.S.

213 <u>Results</u>

214 Report of laboratory-confirmed GAS cases at the University Hospital Zurich between January
215 2012 and December 2023

216 The total number of iGAS strains detected with cultures or molecular techniques from January 217 2012 to December 2023 reported at the University Hospital Zurich is shown in Figure 1. GAS 218 infections typically have a seasonal pattern, showing a peak during late spring in the northern 219 hemisphere [33]. During the COVID-19 pandemic (from March 2020 until the suspension of 220 the pandemic prevention methods in Switzerland, in March 2022), the detection of GAS cases 221 declined compared to the previous years (Suppl. Figure 1) and the number of iGAS was also 222 historically low (Figure 1). In the first quarter of 2023, there was a notable surge in invasive 223 and non-invasive GAS cases, marking a threefold increase compared to the same month 224 average in pre-pandemic years (Figure 1, Suppl. Figure 1). The number of isolated GAS 225 strains remained unusually high throughout the first post-pandemic year.

226

227 Demographic and clinical characteristics of the patients with iGAS infections

228 93 patients, from whom the 93 GAS strains were isolated, were included in this study. The 229 clinical data of 74 patients hospitalized in seven Swiss hospitals were included. The clinical 230 data of the remaining 19 patients (14 from the retrospectively collected strains and five from 231 the prospectively collected ones) could not be retrieved. 44 patients (59.5%) were male with a 232 median age of 47.5 years (range 1 to 94 years), nine (6.5%) were under 18 years of age. 233 Cardiovascular disease (35.1%), diabetes mellitus (17.6%), and solid tumors (9.5%) were the 234 most common comorbidities. The most common diagnosis of infection was skin and soft 235 tissue infection (SSTI) with bacteremia (18.9%), whereas necrotizing fasciitis was diagnosed in five (6.8%) patients. The primary sampling site, representing the majority of cases (64.9%), 236 237 was blood, followed by tissue biopsies (13.5%). Notably, 24.3% of cases featured viral co-238 infections; six patients (8.2%) were diagnosed with influenza and three (4.1%) with SARS-

239 CoV-2, three (4.1%) with a co-infection with SARS-CoV-2 and influenza and three (4.1%)240 with respiratory syncytial virus (RSV). Two patients were diagnosed with varicella zoster 241 virus (VZV) reactivation. Fifteen patients (20.3%) suffered from toxic shock syndrome (TSS). 242 A large number required ICU admission (43.2%) and intubation (29.7%). Surgical 243 debridement was performed in 39 patients (52.7%). Combination antimicrobial therapy was 244 employed in 38 (51.4%) of cases; in 27 of them (71%) clindamycin was co-administered with 245 another antibiotic. Immunoglobulin was administered to all fifteen patients with TSS (20.3%). 246 The average hospitalization duration was 15.6 days, (range 0 - 100 days). We observed an all-247 cause mortality rate of 9.5%, with 6 out of 7 deaths specifically attributed to iGAS. The 248 demographic and clinical characteristics of the patients are summarized in Table 1. 249 The univariable logistic regression analysis revealed significant correlations between ICU 250 admission and viral coinfections (OR 3.600, 95% CI 1.172-11.057). A marginally significant 251 correlation between ICU admission, female sex (OR 0.396, 95% CI 0.152-1.027), and the 252 collapsed variable of obesity, cardiovascular disease and diabetes mellitus (OR 2.500, 95% CI 253 0.954-6.552) was detected (Table 2). All four patients with obesity were admitted to the ICU 254 (p-Fisher 0.03). No significant correlations were found between the investigated patient-255 related variables and the all-cause in-hospital mortality (Suppl. Table 1). A multivariable 256 bimodal logistic regression model for ICU admission confirmed statistically significant 257 coefficients for female sex (OR 0.256, 95% CI 0.081 - 0.804), viral coinfection (OR 4.094, 258 95%CI 1.199-13.986) and the collapsed variable (obesity, cardiovascular disease or diabetes 259 mellitus) (OR 4.595, 95% CI 1.424-14.835) (Table 2). The Nagelkerke R square was 0.256 260 indicating an adequate level of explanatory power and the significance level of the Hosmer-261 Lemeshow test was 0.393 indicating a good model fitting.

262

263 Clinical isolates characteristics

Clinical isolates were genetically characterized to determine their ST and *emm*-type (Table
3). The *emm* typing yielded successful results in 92 out of 93 strains, detecting 18 different *emm* types. Among these, *emm1*-type (*emm1.0, emm 1.2, emm1.3, emm1.6, emm1.7*) emerged
as the predominant type in 63 cases (68%), followed by *emm12 (emm12.0, emm12.2, emm12.4)* in 7 cases (7.6%). The *emm1*-type/ST-28 was prevalent, and associated with higher
mortality, since it was detected in 5/7 (71%) patients who died.

The Kirby-Bauer method was performed on 79 strains in order to determine phenotypical antimicrobial resistance (**Table 3**). All tested strains were susceptible to penicillin. Only one strain was found resistant to clindamycin and erythromycin. No inducible clindamycin resistance was detected.

274

275 Molecular typing of iGAS

276 A comprehensive genomic analysis utilizing WGS was performed on a cohort comprising 91 277 iGAS und 2 non-invasive GAS strains, whose sampling periods spanned through before, 278 during, and after the COVID-19 pandemic (Figure 2A and 2B). Notably, we found a 279 consistent preservation of sequence-types (STs) across all sampling times, indicating genetic 280 stability within the GAS population. Intriguingly, most strains associated with the current 281 GAS upsurge were found to originate from existing genetic lineages circulating before the 282 pandemic, suggesting a continuum in transmission dynamics rather than a pandemic-induced 283 shift. The phylogenies did not exhibit large clusters of recent and post-pandemic strains 284 clearly distinct from the older reference variants refM1uk, ref5005, and ref5448. Ten strains 285 (GAS_086, GAS_032, GAS_031, GAS_082, GAS_070, GAS_027, GAS_052, GAS_046, 286 GAS 076, GAS 048) exhibited a genetic resemblance by core genome phylogeny, possessing 287 different ST types compared to the predominant ST-28 type. These strains were not confined 288 to a specific geographic location but were dispersed throughout the country. A high level of 289 genetic relatedness was found between GAS 035 and GAS 037 strains, originating from a

- 290 patient that died from an iGAS infection and an individual related to the patient, respectively.
- 291 FT-IR spectroscopy showed a poor concordance compared to the core genome analysis
- 292 performed with the WGS, failing to reliably differentiate genetically distant GAS strains (Fig.
- 293 **Suppl. 2**).

294 Discussion

In summary, this multicenter study shows that WGS core genome analysis of GAS strains isolated in Switzerland before, during, and after the COVID-19 pandemic did not reveal genetically distinct, emerging variants. The *emm1* ST28 was predominat in our cohort. FT-IR spectroscopy showed poor overlap with WGS and did not effectively differentiate genetically distant GAS strains, confirming WGS as the current gold standard for the characterization of GAS clinical isolates. Moreover, viral coinfections, mainly influenza and SARS-CoV-2, were significantly associated with a severe iGAS infection requiring an ICU admission.

302 While we found a large *emm1*/ST28 cluster, including the reference strains (refMIuk, ref5005 303 and ref5448), the absence of outbreak characteristics, such as clustered cases in a specific 304 geographical region and a high genetic relatedness within potential transmission chains, 305 suggests that the strains of the current resurgence were part of the diversity already circulating 306 before the COVID-19 pandemic. The emm1/ST28 genotype has been commonly reported 307 causing iGAS infections [34], consistently indicating its dominance over the years [9, 10, 35, 308 36]. Accordingly, we observed that in our cohort *emm1*/ST28 was the predominant variant, 309 present in most patients (5/7) who died from an iGAS infection. Interestingly, we did not find 310 any clusters originating from the three reference strains refM1uk, ref5005 and ref5448, known 311 to cause invasive infections [9, 37, 38]. Furthermore, the phenotypic susceptibility testing 312 revealed a high susceptibility to penicillin, erythromycin and clindamycin, confirming the 313 known susceptibility patterns over the years without a shift towards more resistant strains, as 314 reported worldwide [4, 6, 9].

The COVID-19 pandemic highlighted the need for rapid epidemic diagnosis in controlling outbreaks. To our knowledge, this study is the first to compare the time- and cost-effective FT-IR spectroscopy with WGS for GAS typing and outbreak investigation. FT-IR spectroscopy showed poor overlap with WGS and did not effectively differentiate genetically distant GAS strains. GAS, known for its adaptive nature and highly recombining genome,

undergoes phenotypic changes during invasive infections, potentially impacting FT-IR
spectroscopy's efficacy, a technique reliant on biochemical fingerprints [39, 40]. Our findings
underscore FT-IR spectroscopy's limitations in characterizing GAS strains during outbreaks,
supporting WGS as the gold standard typing method for GAS. Furthermore, WGS is a
valuable tool for GAS characterization, since it can provide important information on *emm*type, virulence factors and antibiotic resistance genes.

326 Our epidemiological records from multiple centers across Switzerland confirm the dramatic 327 increase in iGAS infections, also documented across numerous countries globally [4]. Even 328 though these infections result in about 500,000 deaths annually worldwide, imposing a 329 substantial economic burden [11, 41], data on the incidence of iGAS clinical manifestations 330 remain scarce. At the University Hospital of Zurich, a threefold increase of the number of 331 invasive and non-invasive GAS strains was reported since December 2022 compared to the 332 pre-pandemic years, which aligns with the reports of other countries [6, 9]. Within our study, 333 the most prevalent diagnosis was SSTI, in line with findings from a study conducted in New 334 Zealand [42], followed by primary bacteremia and pneumonia. In accordance with other 335 studies [43], viral coinfections, mostly influenza and SARS-CoV-2, were relatively frequent 336 in our study cohort and significantly associated with a severe disease leading to ICU 337 admission, supporting the current hypothesis linking the recent iGAS infections outbreak to a 338 high prevalence of circulating respiratory viruses [10, 35]. Furthermore, we found that female 339 sex and the metabolic risk factors (cardiovascular disease, obesity and diabetes mellitus) were 340 also significantly associated with a severe disease requiring an ICU support. The all-cause 341 mortality in our cohort was 9.5%, comparable with the data published in England [35], 342 highlighting the severity of iGAS infections.

The cause of the global post-pandemic increased GAS infections prevalence remains elusive. Our findings point out that the recent upsurge does not arise from pathogen-related factors, prompting further exploration of alternative causes, as proposed in prior studies [6, 9, 10, 44].

The current hypothesis suggests that the lack of exposure to GAS and common seasonal respiratory viruses during the COVID-19 pandemic, due to isolation measures, resulted in decreased immunity to GAS and seasonal respiratory viruses [35, 37, 43, 45]. After lifting the COVID-19 pandemic protection measures, an increase and a shift of the seasonal pattern in seasonal respiratory viral and iGAS infections was observed after two years of their historically low incidence.

352 This study has some limitations that affect its broader applicability. The sample origin, limited 353 to specific Swiss regions, may not represent a broader GAS strain diversity. The 354 retrospectively collected subset of data and the unavailability of clinical information for some 355 patients does not allow determining risk factors associated with the current increased iGAS 356 prevalence. Only three of the participating hospitals admitted pediatric patients, leading to an 357 underrepresentation of minors. To draw more decisive conclusions regarding the risk factors 358 of iGAS infections, future studies should include larger, diverse samples cohorts from various 359 regions, encompassing both invasive and non-invasive strains and performing genotypic as 360 well as phenotypic virulence studies.

361 To the best of our knowledge, this is the biggest data set of invasive GAS strains across 362 multiple centers in Switzerland, giving a broad view of the post-pandemic increased prevalence of iGAS infections. The long time-span of the examined GAS strains allowed us to 363 364 explore potential genetic changes before and after the COVID-19 pandemic. The absence of 365 genetic diversity and shift to more resistant strains throughout the years suggests that non-366 pathogen related factors may lead to resurgence of iGAS, supporting the theory that the lack 367 of immunity to GAS and the common respiratory viruses due to the social distancing during 368 the COVID-19 pandemic could be associated with severe iGAS infections with many 369 fatalities.

370 **Conclusion**

371 In summary, our study aimed to investigate the genetic characteristics of GAS strains 372 responsible for the current resurgence of iGAS infection following the COVID-19 pandemic. 373 WGS-based molecular typing did not uncover genetic changes regarding emm-type and 374 sequence-type (ST) pre- during- and post-pandemic Moreover, antibiotic susceptibility testing 375 revealed unchanged susceptibility patterns. The FT-IR spectroscopy limitations in GAS 376 typing underscore the ongoing importance of WGS in molecular analysis. Our results suggest 377 that non-pathogen related factors, such as the lack of immunity to GAS and other common 378 respiratory viruses due to social distancing and wearing masks during the COVID-19 379 pandemic, may be responsible for the post-pandemic increased prevalence of the iGAS 380 infections. Further research is needed to improve surveillance methods of iGAS strains.

References

382	1.	Nelson, G.E., et al., Epidemiology of Invasive Group A Streptococcal Infections in the United
383		<i>States, 2005-2012.</i> Clin Infect Dis, 2016. 63 (4): p. 478-86.DOI: 10.1093/cid/ciw248.
384	2.	Walker, M.J., et al., Disease manifestations and pathogenic mechanisms of Group A
385		Streptococcus. Clin Microbiol Rev, 2014. 27(2): p. 264-301.DOI: 10.1128/cmr.00101-13.
386	3.	Andreoni, F., et al., Clindamycin Affects Group A Streptococcus Virulence Factors and
387		Improves Clinical Outcome. J Infect Dis, 2017. 215(2): p. 269-277.DOI: 10.1093/infdis/jiw229.
388	4.	World Health Organization (15 December 2022). Disease Outbreak News; Increased incidence
389		of scarlet fever and invasive Group A Streptococcus infection - multi-country. Available from:
390		https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON429.
391	5.	Barnes, M., et al., Notes from the Field: Increase in Pediatric Invasive Group A Streptococcus
392		Infections - Colorado and Minnesota, October-December 2022. MMWR Morb Mortal Wkly
393		Rep, 2023. 72 (10): p. 265-267.DOI: 10.15585/mmwr.mm7210a4.
394	6.	Aboulhosn, A., et al., Increases in group A streptococcal infections in the pediatric population
395		in Houston, TX, 2022. Clin Infect Dis, 2023.DOI: 10.1093/cid/ciad197.
396	7.	Increase in Invasive Group A Strep Infections, 2022–2023. 2023 February 2, 2023; Available
397		from: https://www.cdc.gov/groupastrep/igas-infections-investigation.html .
398	8.	Invasive Infektionen mit Gruppe A Streptokokken (iGAS) bei Kindern; Update vom 31. März
399		2023 Statement der PIGS. Available from:
400		https://www.paediatrieschweiz.ch/news/zunahme-invasiver-gruppe-a-streptokokken-
401		<u>infektionen-igas/</u> .
402	9.	Alcolea-Medina, A., et al., The ongoing Streptococcus pyogenes (Group A Streptococcus)
403		outbreak in London, United Kingdom in December 2022: a molecular epidemiology study.
404		Clinical Microbiology and Infection, 2023.DOI: <u>https://doi.org/10.1016/j.cmi.2023.03.001</u> .
405	10.	de Gier, B., et al., Increase in invasive group A streptococcal (Streptococcus pyogenes)
406		infections (iGAS) in young children in the Netherlands, 2022. Euro Surveill, 2023. 28 (1).DOI:
407		10.2807/1560-7917.Es.2023.28.1.2200941.
408	11.	Brouwer, S., et al., Pathogenesis, epidemiology and control of Group A Streptococcus
409		infection. Nat Rev Microbiol, 2023. 21(7): p. 431-447.DOI: 10.1038/s41579-023-00865-7.
410	12.	Bessen, D.E., P.R. Smeesters, and B.W. Beall, Molecular Epidemiology, Ecology, and Evolution
411		of Group A Streptococci. Microbiol Spectr, 2018. 6(5).DOI: 10.1128/microbiolspec.CPP3-0009-
412		2018.
413	13.	Teng, A.S.J., et al., Comparison of fast Fourier transform infrared spectroscopy biotyping with
414		whole genome sequencing-based genotyping in common nosocomial pathogens. Anal Bioanal
415		Chem, 2022. 414(24): p. 7179-7189.DOI: 10.1007/s00216-022-04270-6.
416	14.	Novais, Â., et al., Fourier transform infrared spectroscopy: unlocking fundamentals and
417		prospects for bacterial strain typing. Eur J Clin Microbiol Infect Dis, 2019. 38(3): p. 427-
418		448.DOI: 10.1007/s10096-018-3431-3.
419	15.	Zarnowiec, P., et al., Fourier Transform Infrared Spectroscopy (FTIR) as a Tool for the
420		Identification and Differentiation of Pathogenic Bacteria. Curr Med Chem, 2015. 22(14): p.
421		1710-8.DOI: 10.2174/0929867322666150311152800.
422	16.	Hu, Y., et al., Evaluation of the IR Biotyper for Klebsiella pneumoniae typing and its potentials
423		in hospital hygiene management. Microb Biotechnol, 2021. 14(4): p. 1343-1352.DOI:
424		10.1111/1751-7915.13709.
425	17.	Azrad, M., et al., Comparison of FT-IR with whole-genome sequencing for identification of
426		maternal-to @neonate transmission of antibiotic-resistant bacteria. J Microbiol Methods,
427		2022. 202 : p. 106603.DOI: 10.1016/j.mimet.2022.106603.
428	18.	Martak, D., et al., Fourier-Transform InfraRed Spectroscopy Can Quickly Type Gram-Negative
429		Bacilli Responsible for Hospital Outbreaks. Front Microbiol, 2019. 10: p. 1440.DOI:
430		10.3389/fmicb.2019.01440.

431	19.	Scheier, T.C., et al., Fourier-transform infrared spectroscopy for typing of vancomycin-
432		resistant Enterococcus faecium: performance analysis and outbreak investigation. Microbiol
433		Spectr, 2023. 11 (5): p. e0098423.DOI: 10.1128/spectrum.00984-23.
434	20.	Case definitions for infectious conditions under public health surveillance. Centers for Disease
435		Control and Prevention. MMWR Recomm Rep, 1997. 46 (Rr-10): p. 1-55.
436	21.	Räz, A.K., et al., Limited Adaptation of Staphylococcus aureus during Transition from
437		Colonization to Invasive Infection. Microbiol Spectr, 2023. 11(4): p. e0259021.DOI:
438		10.1128/spectrum.02590-21.
439	22.	Kolesnik-Goldmann, N., et al., Comparison of Disk Diffusion, E-Test, and Broth Microdilution
440		Methods for Testina In Vitro Activity of Cefiderocol in Acinetobacter baumannii. Antibiotics
441		(Basel), 2023, 12 (7),DOI: 10.3390/antibiotics12071212.
442	23.	Kapatai, G., et al., Whole genome sequencing of group A Streptococcus: development and
443		evaluation of an automated pipeline for emmaene typing. PeerJ. 2017. 5 : p. e3226.DOI:
444		10.7717/peeri.3226.
445	24.	Seemann, T., mlst Github.
446	25.	Jolley, K.A. and M.C. Maiden, BIGSdb: Scalable analysis of bacterial genome variation at the
447		population level. BMC Bioinformatics. 2010. 11 : p. 595. DOI: 10.1186/1471-2105-11-595.
448	26.	Bankevich, A., et al., SPAdes: a new genome assembly algorithm and its applications to
449	20.	<i>single-cell sequencing</i> . I Comput Biol. 2012. 19 (5): p. 455-77.DOI: 10.1089/cmb.2012.0021.
450	27	Seemann T. Prokka: ranid prokarvotic genome appotation Bioinformatics 2014 30 (14); p
451	_ / ·	2068-9 DOI: 10 1093/bioinformatics/btu153
452	28	Page A L et al Roary: rapid large-scale prokaryote pan genome analysis Bioinformatics
453	20.	2015 31 (22) [,] n 3691-3 DOI [,] 10.1093/bioinformatics/btv421
454	29	Pritchard L et al. Genomics and taxonomy in diagnostics for food security: soft-rotting
455	201	enterobacterial plant nathogens. Analytical Methods. 2016. 8(1): n. 12-24 DOI:
456		10 1039/C5AY02550H
457	30	Nguyen T et al IO-TREF: a fast and effective stochastic algorithm for estimating
458	00.	maximum-likelihood phylogenies Mol Biol Evol 2015 32 (1): p. 268-74 DOI:
459		10 1093/molbev/msu300
460	31	Paradis E and K Schliep are 5.0 an environment for modern phylogenetics and
461	01	evolutionary analyses in <i>B</i> Bioinformatics 2019 35 (3): n 526-528 DOI:
462		10 1093/bioinformatics/btv633
463	32	Yu G et al. gatree: an r package for visualization and annotation of phylogenetic trees with
464	02.	their covariates and other associated data. Methods in Ecology and Evolution, 2017, 8(1): p.
465		28-36 DOI: https://doi.org/10.1111/2041-210X.12628
466	33	Kennis M et al. Seasonal variations and risk factors of Streptococcus progenes infection: a
467	55.	multicenter research network study. Ther Adv Infect Dis 2022 9 n
468		20499361221132101 DOI: 10 1177/20499361221132101
469	34	Ekelund K et al. Variations in emm type among aroun A streptococcal isolates causing
470	54.	invasive or noninvasive infections in a nationwide study 1 Clin Microhiol 2005 43 (7): n
470		3101-9 DOI: 10 1128/icm 43 7 3101-3109 2005
472	35	Guy R et al. Increase in invasive aroun A strentococcal infection notifications England
173	55.	2022 Euro Surveill 2023 28 (1) DOI: 10.2807/1560-7917 Es.2023.28.1.2200942
475	36	Gherardi G. I. A. Vitali and R. Creti Prevalent emm Types among Invasive GAS in Europe and
474	50.	North America since Year 2000 Front Public Health 2018 6: n 59 DOI:
475		10 3389/fmuhh 2018 00059
470	37	Peetermans M et al. Clinical and molecular enidemiological features of critically ill patients
478	57.	with invasive aroun A Strentococcus infections: a Relation multicenter case-series App
479		Intensive Gare 2024 $14(1)$ n 19 DOI: 10.1186/s13613-024-01249-7
480	38	Wilkening RV and MI Federle Evolutionary Constraints Shaping Streptococcus puggenes
481	50.	Host Interactions Trends Microbiol 2017 25 (7) n 562-572 DOI: 10.1016/i tim 2017.01.007
- U L		

482 39. Feil, E.J., et al., Recombination within natural populations of pathogenic bacteria: short-term 483 empirical estimates and long-term phylogenetic consequences. Proc Natl Acad Sci U S A, 484 2001. 98(1): p. 182-7.DOI: 10.1073/pnas.98.1.182. Bao, Y.-J., et al., Phenotypic differentiation of Streptococcus pyogenes populations is induced 485 40. 486 by recombination-driven gene-specific sweeps. Scientific Reports, 2016. 6(1): p. 36644.DOI: 487 10.1038/srep36644. 488 41. Carapetis, J.R., et al., The global burden of group A streptococcal diseases. Lancet Infect Dis, 489 2005. 5(11): p. 685-94.DOI: 10.1016/s1473-3099(05)70267-x. 490 42. Cannon, J.W., et al., The economic and health burdens of diseases caused by group A 491 Streptococcus in New Zealand. Int J Infect Dis, 2021. 103: p. 176-181.DOI: 492 10.1016/j.ijid.2020.11.193. 493 43. de Gier, B., et al., Associations between common respiratory viruses and invasive group A 494 streptococcal infection: A time-series analysis. Influenza Other Respir Viruses, 2019. 13(5): p. 495 453-458.DOI: 10.1111/irv.12658. 496 44. Ramos Amador, J.T., A. Berzosa Sánchez, and M. Illán Ramos, Group A Streptococcus invasive 497 infection in children: Epidemiologic changes and implications. Rev Esp Quimioter, 2023. 36 498 Suppl 1(Suppl 1): p. 33-36.DOI: 10.37201/req/s01.09.2023. 499 45. Nygaard, U., et al., Invasive group A streptococcal infections in children and adolescents in 500 Denmark during 2022-23 compared with 2016-17 to 2021-22: a nationwide, multicentre, 501 population-based cohort study. Lancet Child Adolesc Health, 2024. 8(2): p. 112-121.DOI: 502 10.1016/s2352-4642(23)00295-x.

504 Figures

Figure 1 - Number of detected invasive GAS strains at the University Hospital Zurich
between January 2012 and December 2023

Invasive GAS (iGAS) strains detected either by culturing or via molecular methods are included in this graph. The blue color indicates the number of new cases monthly and the red color the moving average every three months. Q1: months from January to March, Q2: months from April to June, Q3: months from July to September, Q4: months from October to December.

512

Figure 2 - Phylogenetic tree of the 93 GAS clinical isolates and three reference strains (refM1uk, ref5005 and ref5448)

515 Midpoint rooted maximum likelihood phylogenetic trees based on the alignment of the 516 clinical isolates and reference strains core genes. The scale bar corresponds to the number of 517 nucleotide substitutions per position. **A**. Phylogenic tree of all GAS clinical isolates and the 518 three reference strains (refM1uk, ref5005 and ref5448). **B**. Magnified representation of the 519 large *emm1*/ST28 cluster (including refM1uk, ref5005 and ref5448) from panel A.

520

521 Table 1. Demographic and clinical characteristics of the patients with invasive GAS522 infections

523

Table 2. Results of the univariable and multivariable logistic regression analysis of the association of patient-related factors with ICU admission (n=32) upon iGAS infection.

526

527 **Table 3.** Molecular and microbiological characteristics of the 93 GAS clinical isolates.

529	Supplementary Figure 1 - Number of detected GAS strains (invasive and non-invasive)
530	at the University Hospital Zurich between January 2012 and December 2023
531	Invasive and non-invasive GAS strains detected either by culturing or via molecular methods
532	are included in this graph. The blue color indicates the number of new cases monthly and the
533	red color the moving average every three months. Q1: months from January to March, Q2:
534	months from April to June, Q3: months from July to September, Q4: months from October to
535	December.
536	
537	Supplementary Figure 2 - Assessment of average nucleotide identity (ANI) networks
538	with FT-IR spectroscopy

539 Overlap (quantified as the v-measure) between FT-IR and ANI-derived clusters for different
540 cutoffs used for FT-IR (X-axis) and ANI (color) clustering.

541

Supplementary Table 1. Results of the univariable and multivariable logistic regression
analysis of the association of patient-related factors with all-cause in-hospital mortality (n=7)
upon iGAS infection.

Number of iGAS strains detection













Characteristics (N=74)	
Sex, n (%)	
Male	44 (59.5)
Female	30 (40.5)
Median age (range), years	47.5 (1-94)
Patients < 18 years old, n (%)	9 (6.5)
Hospital, n (%)	
University Hospital of Zurich	20 (27)
University Hospital of Geneva	17 (23)
City Hospital Zurich	16 (21.6)
Wetzikon Hospital	9 (12.2)
Cantonal Hospital Chur	7 (9.5)
Uster Hospital	4 (5.4)
Cantonal Hospital Winterthur	1 (1.4)
Coexisting conditions, n (%)	
Cardiovascular disease	26 (35.1)
Diabetes mellitus	13 (17.6)
Renal disease	8 (10.8)
Solid tumortumour	7 (9.5)
Alcohol abuse	6 (8.1)
Intravenous drug use	5 (6.8)
Immunosuppression	4 (5.4)
Adipositas	4 (5.4)
Chronic obstructive lung disease	3 (4.1)
Autoimmune disease	2 (2.7)
Viral hepatitis	2 (2.7)
HIV	1 (1.4)
HematologicalHaematological malignancy	0 (0)
No underlying disease, n (%)	30 (40.5)
≥ 1 underlying disease, n (%)	44 (59.5)
Homeless	2 (2.7)
Sampling site, n (%)	
Blood	48 (64.9)

Swab5 (6.8)Joint fluid3 (4.1)Pleural fluid3 (4.1)Abscess3 (4.1)Bone biopsy1 (1.4)Bone biopsy1 (1.4)Ascites1 (1.4)Diagnosis, n (%)	Tissue biopsy	10 (13.5)
Joint fluid3 (4.1)Pleural fluid3 (4.1)Abscess3 (4.1)Bone biopsy1 (1.4)Ascites1 (1.4)Diagnosis, n (%)	Swab	5 (6.8)
Pleural fluid3 (4.1)Abscess3 (4.1)Bone biopsy1 (1.4)Ascites1 (1.4)Diagnosis, n (%)	Joint fluid	3 (4.1)
Abscess3 (4.1)Bone biopsy1 (1.4)Ascites1 (1.4)Diagnosis, n (%)	Pleural fluid	3 (4.1)
Bone biopsy1 (1.4)Ascites1 (1.4)Diagnosis, n (%)	Abscess	3 (4.1)
Ascites1 (1.4)Diagnosis, n (%)14 (18.9)SSTI with bacteraemia14 (18.9)Pneumonia12 (16.2)Isolated bacteraemia10 (13.5)SSTI without bacteraemia5 (6.8)Necrotizing fasciitis5 (6.8)Septic arthritis5 (6.8)Non pregnancy related endometritis3 (4.1)Osteomyelitis3 (4.1)Tonsilitis with abscess3 (4.1)Septic bursitis3 (4.1)Otitis media/mastoiditis with bacteraemia2 (2.7)Otitis media/mastoiditis with bacteraemia2 (2.7)Tonsilitis with abscess2 (2.7)Pharyngitis with bacteraemia1 (1.4)Meningitis1 (1.4)Pregnancy related endometritis1 (1.4)Mediastinitis1 (1.4)Meningitis1 (1.4)Influenza (A or B)6 (8.2)SARS-CoV-23 (4.1)SARS-CoV-2 and Influenza (A or B)3 (4.1)RSV3 (4.1)	Bone biopsy	1 (1.4)
Diagnosis, n (%)14 (18.9)SSTI with bacteraemia12 (16.2)Isolated bacteraemia10 (13.5)SSTI without bacteraemia10 (13.5)SSTI without bacteraemia5 (6.8)Necrotizing fasciitis5 (6.8)Septic arthritis5 (6.8)Non pregnancy related endometritis3 (4.1)Osteomyelitis3 (4.1)Tonsilitis with abscess3 (4.1)Septic bursitis3 (4.1)Ottitis media/mastoiditis without bacteraemia2 (2.7)Otitis media/mastoiditis with bacteraemia2 (2.7)Tonsilitis with bacteraemia1 (1.4)Meningitis1 (1.4)Pregnancy related endometritis1 (1.4)Mediastinitis1 (1.4)Meningitis1 (1.4)Mediastinitis1 (1.4)Influenza (A or B)6 (8.2)SARS-CoV-23 (4.1)RSV3 (4.1)	Ascites	1 (1.4)
SSTI with bacteraemia14 (18.9)Pneumonia12 (16.2)Isolated bacteraemia10 (13.5)SSTI without bacteraemia5 (6.8)Necrotizing fasciitis5 (6.8)Septic arthritis3 (4.1)Osteomyelitis3 (4.1)Osteomyelitis3 (4.1)Tonsilitis with abscess3 (4.1)Septic bursitis3 (4.1)Otitis media/mastoiditis without bacteraemia2 (2.7)Otitis media/mastoiditis with bacteraemia2 (2.7)Otitis media/mastoiditis with bacteraemia2 (2.7)Pharyngitis with bacteraemia1 (1.4)Meningitis1 (1.4)Pregnancy related endometritis1 (1.4)Mediastinitis1 (1.4)Fregnancy related endometritis1 (1.4)Inducarditis1 (1.4)Septic shock syndrome, n (%)32 (43.5)Viral co-infection, n (%)18 (24.3)Influenza (A or B)6 (8.2)SARS-CoV-23 (4.1)RSV3 (4.1)	Diagnosis, n (%)	
Pneumonia12 (16.2)Isolated bacteraemia10 (13.5)SSTI without bacteraemia5 (6.8)Necrotizing fasciitis5 (6.8)Septic arthritis5 (6.8)Non pregnancy related endometritis3 (4.1)Osteomyelitis3 (4.1)Tonsilitis with abscess3 (4.1)Septic bursitis3 (4.1)Otitis media/mastoiditis without bacteraemia2 (2.7)Otitis media/mastoiditis with bacteraemia2 (2.7)Otitis media/mastoiditis with bacteraemia2 (2.7)Pharyngitis with obscess2 (2.7)Pharyngitis with bacteraemia1 (1.4)Meningitis1 (1.4)Mediastinitis1 (1.4)Endocarditis1 (1.4)Toxic shock syndrome, n (%)32 (43.5)Viral co-infection, n (%)18 (24.3)Influenza (A or B)6 (8.2)SARS-CoV-2 and Influenza (A or B)3 (4.1)RSV3 (4.1)	SSTI with bacteraemia	14 (18.9)
Isolated bacteraemia10 (13.5)SSTI without bacteraemia5 (6.8)Necrotizing fasciitis5 (6.8)Septic arthritis5 (6.8)Non pregnancy related endometritis3 (4.1)Osteomyelitis3 (4.1)Tonsilitis with abscess3 (4.1)Septic bursitis3 (4.1)Otitis media/mastoiditis without bacteraemia2 (2.7)Otitis media/mastoiditis with bacteraemia2 (2.7)Tonsilitis without abscess2 (2.7)Pharyngitis with bacteraemia1 (1.4)Meningitis1 (1.4)Pregnancy related endometritis1 (1.4)Endocarditis1 (1.4)Toxic shock syndrome, n (%)15 (20.3)Septic shock, n (%)32 (43.5)Viral co-infection, n (%)18 (24.3)Influenza (A or B)6 (8.2)SARS-CoV-23 (4.1)RSV3 (4.1)	Pneumonia	12 (16.2)
SSTI without bacteraemia5 (6.8)Necrotizing fasciitis5 (6.8)Septic arthritis5 (6.8)Non pregnancy related endometritis3 (4.1)Osteomyelitis3 (4.1)Tonsilitis with abscess3 (4.1)Septic bursitis3 (4.1)Otitis media/mastoiditis without bacteraemia2 (2.7)Otitis media/mastoiditis with bacteraemia2 (2.7)Tonsilitis with bacteraemia2 (2.7)Pharyngitis with bacteraemia1 (1.4)Meningitis1 (1.4)Pregnancy related endometritis1 (1.4)Endocarditis1 (1.4)Toxic shock syndrome, n (%)15 (20.3)Septic shock, n (%)32 (43.5)Viral co-infection, n (%)18 (24.3)Influenza (A or B)6 (8.2)SARS-CoV-23 (4.1)RSV3 (4.1)	Isolated bacteraemia	10 (13.5)
Necrotizing fasciitis5 (6.8)Septic arthritis5 (6.8)Non pregnancy related endometritis3 (4.1)Osteomyelitis3 (4.1)Tonsilitis with abscess3 (4.1)Septic bursitis3 (4.1)Otitis media/mastoiditis without bacteraemia2 (2.7)Otitis media/mastoiditis with bacteraemia2 (2.7)Otitis media/mastoiditis with bacteraemia2 (2.7)Pharyngitis without abscess2 (2.7)Pharyngitis with bacteraemia1 (1.4)Meningitis1 (1.4)Mediastinitis1 (1.4)Endocarditis1 (1.4)Toxic shock syndrome, n (%)15 (20.3)Septic shock, n (%)32 (43.5)Viral co-infection, n (%)18 (24.3)Influenza (A or B)6 (8.2)SARS-CoV-23 (4.1)SARS-CoV-2 and Influenza (A or B)3 (4.1)RSV3 (4.1)	SSTI without bacteraemia	5 (6.8)
Septic arthritis5 (6.8)Non pregnancy related endometritis3 (4.1)Osteomyelitis3 (4.1)Tonsilitis with abscess3 (4.1)Septic bursitis3 (4.1)Otitis media/mastoiditis without bacteraemia2 (2.7)Otitis media/mastoiditis with bacteraemia2 (2.7)Tonsilitis without abscess2 (2.7)Pharyngitis with bacteraemia1 (1.4)Meningitis1 (1.4)Pregnancy related endometritis1 (1.4)Endocarditis1 (1.4)Toxic shock syndrome, n (%)15 (20.3)Septic shock, n (%)18 (24.3)Influenza (A or B)6 (8.2)SARS-CoV-23 (4.1)SARS-CoV-2 and Influenza (A or B)3 (4.1)RSV3 (4.1)	Necrotizing fasciitis	5 (6.8)
Non pregnancy related endometritis3 (4.1)Osteomyelitis3 (4.1)Tonsilitis with abscess3 (4.1)Septic bursitis3 (4.1)Otitis media/mastoiditis without bacteraemia2 (2.7)Otitis media/mastoiditis with bacteraemia2 (2.7)Tonsilitis without abscess2 (2.7)Pharyngitis with bacteraemia1 (1.4)Meningitis1 (1.4)Pregnancy related endometritis1 (1.4)Endocarditis1 (1.4)Toxic shock syndrome, n (%)15 (20.3)Septic shock, n (%)32 (43.5)Viral co-infection, n (%)18 (24.3)Influenza (A or B)6 (8.2)SARS-CoV-23 (4.1)RSV3 (4.1)	Septic arthritis	5 (6.8)
Osteomyelitis3 (4.1)Tonsilitis with abscess3 (4.1)Septic bursitis3 (4.1)Otitis media/mastoiditis without bacteraemia2 (2.7)Otitis media/mastoiditis with bacteraemia2 (2.7)Tonsilitis without abscess2 (2.7)Pharyngitis with bacteraemia1 (1.4)Meningitis1 (1.4)Pregnancy related endometritis1 (1.4)Endocarditis1 (1.4)Toxic shock syndrome, n (%)15 (20.3)Septic shock, n (%)18 (24.3)Influenza (A or B)6 (8.2)SARS-CoV-23 (4.1)SARS-CoV-2 and Influenza (A or B)3 (4.1)RSV3 (4.1)	Non pregnancy related endometritis	3 (4.1)
Tonsilitis with abscess3 (4.1)Septic bursitis3 (4.1)Otitis media/mastoiditis without bacteraemia2 (2.7)Otitis media/mastoiditis with bacteraemia2 (2.7)Tonsilitis without abscess2 (2.7)Pharyngitis with bacteraemia1 (1.4)Meningitis1 (1.4)Pregnancy related endometritis1 (1.4)Mediastinitis1 (1.4)Endocarditis1 (1.4)Toxic shock syndrome, n (%)15 (20.3)Septic shock, n (%)32 (43.5)Viral co-infection, n (%)18 (24.3)Influenza (A or B)6 (8.2)SARS-CoV-23 (4.1)SARS-CoV-2 and Influenza (A or B)3 (4.1)RSV3 (4.1)	Osteomyelitis	3 (4.1)
Septic bursitis3 (4.1)Otitis media/mastoiditis without bacteraemia2 (2.7)Otitis media/mastoiditis with bacteraemia2 (2.7)Tonsilitis without abscess2 (2.7)Pharyngitis with bacteraemia1 (1.4)Meningitis1 (1.4)Pregnancy related endometritis1 (1.4)Mediastinitis1 (1.4)Endocarditis1 (1.4)Toxic shock syndrome, n (%)15 (20.3)Septic shock, n (%)32 (43.5)Viral co-infection, n (%)18 (24.3)Influenza (A or B)6 (8.2)SARS-CoV-23 (4.1)SARS-CoV-2 and Influenza (A or B)3 (4.1)RSV3 (4.1)	Tonsilitis with abscess	3 (4.1)
Otitis media/mastoiditis without bacteraemia2 (2.7)Otitis media/mastoiditis with bacteraemia2 (2.7)Tonsilitis without abscess2 (2.7)Pharyngitis with bacteraemia1 (1.4)Meningitis1 (1.4)Pregnancy related endometritis1 (1.4)Mediastinitis1 (1.4)Endocarditis1 (1.4)Toxic shock syndrome, n (%)15 (20.3)Septic shock, n (%)32 (43.5)Viral co-infection, n (%)18 (24.3)Influenza (A or B)6 (8.2)SARS-CoV-23 (4.1)SARS-CoV-2 and Influenza (A or B)3 (4.1)RSV3 (4.1)	Septic bursitis	3 (4.1)
Otitis media/mastoiditis with bacteraemia2 (2.7)Tonsilitis without abscess2 (2.7)Pharyngitis with bacteraemia1 (1.4)Meningitis1 (1.4)Pregnancy related endometritis1 (1.4)Mediastinitis1 (1.4)Endocarditis1 (1.4)Toxic shock syndrome, n (%)15 (20.3)Septic shock, n (%)32 (43.5)Viral co-infection, n (%)18 (24.3)Influenza (A or B)6 (8.2)SARS-CoV-23 (4.1)SARS-CoV-2 and Influenza (A or B)3 (4.1)RSV3 (4.1)	Otitis media/mastoiditis without bacteraemia	2 (2.7)
Tonsilitis without abscess2 (2.7)Pharyngitis with bacteraemia1 (1.4)Meningitis1 (1.4)Pregnancy related endometritis1 (1.4)Mediastinitis1 (1.4)Endocarditis1 (1.4)Toxic shock syndrome, n (%)15 (20.3)Septic shock, n (%)32 (43.5)Viral co-infection, n (%)18 (24.3)Influenza (A or B)6 (8.2)SARS-CoV-23 (4.1)SARS-CoV-2 and Influenza (A or B)3 (4.1)RSV3 (4.1)	Otitis media/mastoiditis with bacteraemia	2 (2.7)
Pharyngitis with bacteraemia1 (1.4)Meningitis1 (1.4)Pregnancy related endometritis1 (1.4)Mediastinitis1 (1.4)Endocarditis1 (1.4)Toxic shock syndrome, n (%)15 (20.3)Septic shock, n (%)32 (43.5)Viral co-infection, n (%)18 (24.3)Influenza (A or B)6 (8.2)SARS-CoV-23 (4.1)SARS-CoV-2 and Influenza (A or B)3 (4.1)RSV3 (4.1)	Tonsilitis without abscess	2 (2.7)
Meningitis1 (1.4)Pregnancy related endometritis1 (1.4)Mediastinitis1 (1.4)Endocarditis1 (1.4)Toxic shock syndrome, n (%)15 (20.3)Septic shock, n (%)32 (43.5)Viral co-infection, n (%)18 (24.3)Influenza (A or B)6 (8.2)SARS-CoV-23 (4.1)SARS-CoV-2 and Influenza (A or B)3 (4.1)RSV3 (4.1)	Pharyngitis with bacteraemia	1 (1.4)
Pregnancy related endometritis1 (1.4)Mediastinitis1 (1.4)Endocarditis1 (1.4)Toxic shock syndrome, n (%)15 (20.3)Septic shock, n (%)32 (43.5)Viral co-infection, n (%)18 (24.3)Influenza (A or B)6 (8.2)SARS-CoV-23 (4.1)SARS-CoV-2 and Influenza (A or B)3 (4.1)RSV3 (4.1)	Meningitis	1 (1.4)
Mediastinitis 1 (1.4) Endocarditis 1 (1.4) Toxic shock syndrome, n (%) 15 (20.3) Septic shock, n (%) 32 (43.5) Viral co-infection, n (%) 18 (24.3) Influenza (A or B) 6 (8.2) SARS-CoV-2 3 (4.1) SARS-CoV-2 and Influenza (A or B) 3 (4.1) RSV 3 (4.1)	Pregnancy related endometritis	1 (1.4)
Endocarditis 1 (1.4) Toxic shock syndrome, n (%) 15 (20.3) Septic shock, n (%) 32 (43.5) Viral co-infection, n (%) 18 (24.3) Influenza (A or B) 6 (8.2) SARS-CoV-2 3 (4.1) SARS-CoV-2 and Influenza (A or B) 3 (4.1) RSV 3 (4.1)	Mediastinitis	1 (1.4)
Toxic shock syndrome, n (%) 15 (20.3) Septic shock, n (%) 32 (43.5) Viral co-infection, n (%) 18 (24.3) Influenza (A or B) 6 (8.2) SARS-CoV-2 3 (4.1) SARS-CoV-2 and Influenza (A or B) 3 (4.1) RSV 3 (4.1)	Endocarditis	1 (1.4)
Septic shock, n (%) 32 (43.5) Viral co-infection, n (%) 18 (24.3) Influenza (A or B) 6 (8.2) SARS-CoV-2 3 (4.1) SARS-CoV-2 and Influenza (A or B) 3 (4.1) RSV 3 (4.1)	Toxic shock syndrome, n (%)	15 (20.3)
Viral co-infection, n (%) 18 (24.3) Influenza (A or B) 6 (8.2) SARS-CoV-2 3 (4.1) SARS-CoV-2 and Influenza (A or B) 3 (4.1) RSV 3 (4.1)	Septic shock, n (%)	32 (43.5)
Influenza (A or B) 6 (8.2) SARS-CoV-2 3 (4.1) SARS-CoV-2 and Influenza (A or B) 3 (4.1) RSV 3 (4.1)	Viral co-infection, n (%)	18 (24.3)
SARS-CoV-2 3 (4.1) SARS-CoV-2 and Influenza (A or B) 3 (4.1) RSV 3 (4.1)	Influenza (A or B)	6 (8.2)
SARS-CoV-2 and Influenza (A or B) 3 (4.1) RSV 3 (4.1)	SARS-CoV-2	3 (4.1)
RSV 3 (4.1)	SARS-CoV-2 and Influenza (A or B)	3 (4.1)
	RSV	3 (4.1)

VZV	2 (2.7)
Rhinovirus	1 (1.4)
ICU admission, n (%)	32 (43.2)
Intubation, n (%)	22 (29.7)
Surgery, n (%)	39 (52.7)
Amputation, n (%)	4 (5.4)
Antimicrobial therapy, n (%)	
Co-Amoxicillin-Clavulanate	39 (52.7)
Clindamycin	36 (48.6)
CeftriaxonCeftriaxone	26 (35.1)
Penicillin	21(28.4)
Piperacillin-Tazobactam	15 (20.3)
Vancomycin	9 (12.2)
Meropenem	4 (5.4)
Clarithromycin	3 (4.1)
Cefepime	3 (4.1)
Gentamycin	2 (2.7)
Combination therapy, n (%)	38 (51.4)
Immunoglobulin, n (%)	15 (20.3)
Duration of hospitalization, mean (range), days	15.6 (0-100)
Duration of ICU hospitalization, mean (range), days	3.2 (0-21)
All-cause mortality, n (%)	7 (9.5)
GAS-related death, n (%)	6 (8.1)

HIV: Human Immunodeficiency Virus, SSTI: Skin and soft tissue infections, ICU: Intensive Care Unit, GAS: Group A Streptococci, SARS-CoV-2: Severe acute respiratory syndrome coronavirus type 2, RSV: Respiratory Syncytial Virus, VZV: Varicella zoster virus

	Odds Ratio	95% Confidence Intervall	p value
Univariable analysis			
Female sex	0.396	0.152, 1.027	0.057
Cardiovascular disease	1.944	0.739, 5.116	0.178
COPD	0.645	0.056, 7.445	0.725
Diabetes mellitus	1.680	0.504, 5.600	0.398
Solid tumour	0.194	0.022, 1.696	0.138
Immunosuppression	0.419	0.042, 4.232	0.461
Alcohol abuse	1.345	0.253, 7.150	0.728
Renal disease	0.766	0.169, 3.471	0.729
Viral coinfection	3.600	1.172, 11.057	0.062
Collapsed metabolic Variable	2.500	0.954, 6.552	
Multivariable analysis			
Sex	0.256	0.081, 0.804	0.020
Collapsed Metabolic Variable	4.595	1.424, 14.835	0.011
Viral coinfection	4.094	1.199, 13.986	0.025
Constant	0.651		0.336

COPD: chronic obstructive pulmonary disease, HIV: human immunodeficiency virus, IBD: inflammatory bowel disease, Collapsed Metabolic Variable: cardiovascular disease, diabetes mellitus and obesity

						Inhibition zone (mm			
Nr.	Strain ID	Lab ID	Isolation						
			year	ST	emm type	PEN	ERM	CLI	
1	GAS_001	23021066	2022	28	1.0	27	26	23	
2	GAS_002	23021067	2023	39	4.0	22	22	19	
3	GAS_003	23021068	2023	28	1.3	29	27	23	
4	GAS_004	23021069	2023	28	1.0	26	24	18	
5	GAS_005	23021070	2023	28	1.3	30	28	23	
6	GAS_006	23021071	2023	28	1.3	34	31	26	
7	GAS_007	CI1224	2017	28	NA	NA	NA	NA	
8	GAS_008	CI1271	2017	28	1.0	NA	NA	NA	
9	GAS_009	CI1296	2017	28	1.0	NA	NA	NA	
10	GAS_010	CI1316	2017	28	1.0	NA	NA	NA	
11	GAS_011	CI1453	2018	28	1.0	NA	NA	NA	
12	GAS_012	CI1800	2019	1138	1.0	32	29	23	
13	GAS_013	CI2261	2019	101	1.0	NA	NA	NA	
14	GAS_014	CI348	2013	28	1.0	NA	NA	NA	
15	GAS_015	CI350	2013	28	1.0	NA	NA	NA	
16	GAS_016	CI407	2013	52	28	NA	NA	NA	
17	GAS_017	CI4711	2020	63	77.0	30	12	25	
18	GAS_018	CI4839	2020	28	1.0	33	31	25	
19	GAS_019	CI5359	2020	59	8.0	37	32	27	
20	GAS_020	CI543	2013	28	1.0	NA	NA	NA	
21	GAS_021	CI6416	2020	267	1.0	24	22	20	
22	GAS_022	CI655	2014	NA	28	NA	NA	NA	
23	GAS_023	CI729	2015	167	118	NA	NA	NA	
24	GAS_024	CI7790	2021	403	11.1	31	6	9	
25	GAS_025	CI780	2015	167	118	NA	NA	NA	
26	GAS_026	CI781	2015	101	89	NA	NA	NA	
27	GAS_027	CI8226	2023	242	12.4	30	28	22	
28	GAS_028	CI8227	2023	28	1.3	32	29	23	
29	GAS_029	CI8236	2023	28	1.0	25	24	19	
30	GAS_030	CI8237	2023	28	1.0	32	28	22	
31	GAS_031	CI8239	2023	242	12.4	33	30	24	
32	GAS_032	CI8240	2023	242	1.3	30	28	22	
33	GAS_033	CI8241	2023	28	1.3	31	28	23	
34	GAS_034	CI8242	2023	28	1.0	32	29	23	
35	GAS_035	CI8243	2023	28	1.0	33	30	24	
36	GAS_036	CI8244	2023	28	1.0	33	29	24	
37	GAS_037	CI8245	2023	28	1.0	31	28	23	
38	GAS_038	CI8248	2023	28	1.0	31	29	23	
39	GAS_039	CI8249	2023	28	1.0	27	26	22	
40	GAS_040	CI8252	2022	28	1.0	30	29	23	
41	GAS_041	CI8253	2022	28	1.0	31	29	23	
42	GAS_042	CI8254	2022	28	1.0	31	29	23	
43	GAS_043	CI8255	2023	28	1.0	32	29	23	

44	GAS_044	CI8256	2023	28	1.0	33	28	22
45	GAS_045	CI8257	2023	28	1.0	31	29	23
46	GAS_046	CI8258	2023	36	12	31	28	23
47	GAS_047	CI8259	2023	28	1.0	32	28	23
48	GAS_048	CI8260	2023	36	12	32	28	23
49	GAS_049	CI8261	2023	62	1.0	34	30	24
50	GAS_050	CI8262	2023	28	1.0	29	28	22
51	GAS_051	CI8263	2023	28	1.0	32	29	23
52	GAS_052	CI8265	2023	36	12	32	28	23
53	GAS_053	CI8266	2023	46	22	35	14	31
54	GAS_054	CI8267	2022	39	1.0	26	26	21
55	GAS_055	CI8268	2022	28	1.0	24	26	22
56	GAS_056	CI8269	2023	28	1.0	24	22	18
57	GAS_057	CI8270	2023	28	1.0	26	22	19
58	GAS_058	CI8273	2023	148	1.3	29	26	21
59	GAS_059	CI8274	2023	28	1.3	33	28	23
60	GAS_060	CI8277	2023	28	1.0	28	24	19
61	GAS_061	CI8278	2023	28	1.0	22	23	18
62	GAS_062	CI8279	2022	28	1.0	31	30	19
63	GAS_063	CI8280	2023	314	1.0	25	12	17
64	GAS_064	CI8453	2022	28	1.0	32	29	23
65	GAS_065	CI8466	2022	101	1.0	27	25	19
66	GAS_066	CI8467	2022	28	1.0	33	28	22
67	GAS_067	CI9366	2023	28	1.4	29	25	22
68	GAS_068	CI9367	2023	101	89.4	27	28	22
69	GAS_069	CI9368	2023	62	87.9	26	23	21
70	GAS_070	CI9370	2023	242	12.4	24	22	22
71	GAS_071	CI9375	2022	28	1.7	27	24	19
72	GAS_072	CI9376	2022	28	1.4	27	24	21
73	GAS_073	CI9377	2022	28	1.7	34	32	30
74	GAS_074	CI9378	2022	178	44.0	24	24	20
75	GAS_075	CI9379	2022	190	49.3	28	28	22
76	GAS_076	CI9380	2022	36	12.2	19	22	18
77	GAS_077	CI9381	2022	NA	73.0	26	26	23
78	GAS_078	CI9382	2022	NA	80.0	30	30	27
79	GAS_079	CI9384	2022	137	104.0	33	30	25
80	GAS_080	CI9385	2022	190	49.3	27	26	21
81	GAS_081	CI9387	2022	28	1.4	31	31	24
82	GAS_082	CI9389	2022	242	252.0	26	24	22
83	GAS_083	CI9390	2022	150	212.0	26	26	22
84	GAS_084	FFU9/16211	2021	772	89.0	35	26	25
85	GAS_085	FS42596242	2022	11	53.0	30	26	25
86	GAS_086	FS49301899	2022	242	1.0	28	23	21
87	GAS_087	FS49818997	2022	28	1.0	32	33	24
00		FS55545334	2022	060	1.0 and	22	20	20
00		5560217400	2022	צסצ	00.2 1.0	22	2ð 24	20
89	0A2_089	130321/489	2023	28	1.0	27	24	22

90	GAS_090	FS72033123	2023	28	1.0	28	29	22
91	GAS_091	FS72033369	2023	28	1.0	30	24	22
92	GAS_092	FS72034424	2023	52	1.0	27	24	21
93	GAS_093	FS72034435	2023	28	1.0	29	24	20

NA: not available